 |
| September 2011 Volume : 1 Issue : 2 |
Turning the promise of genomics into the practice of medicine™ |
|
 |
 |
Announcements |
|
|
 |
Colon Cancer Coach |
| |
My Colon Cancer Coach is a tool designed to help patients... |
| |
» More |
|
|
|
|
|
 |
|
|
|
|
 |
Events & Online Resources |
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
| Welcome to the Oncotype DX® Colon Cancer Assay Newsletter |
| The goal of this newsletter is to provide those who are interested in genomics with quarterly updates of relevant information from Genomic Health, Inc. with a specific focus on the Oncotype DX Colon Cancer Assay. If you do not wish to receive this newsletter, please refer to the information listed at the bottom of this e-mail to unsubscribe. |
|
|
|
|
|
|
|
|
|
|
 |
Featured Articles In THIS ISSUE |
|
|
 |
CALGB Overview |
| |
An overview of CALGB 9581, a confirmatory story of the Oncotype DX Colon Cancer Assay, presented at ASCO 2011.
|
| |
» More |
|
|
|
QUASAR Multivariate Analysis Spotlight |
| |
When a new tumor marker such as Recurrence Score is introduced, it is important to know whether it predicts clinical outcome such as risk of recurrence... |
| |
» More |
|
|
|
Analytical Validation |
| |
Analytical validation is the assessment of assay performance characteristics and the optimal conditions to ensure consistent and reliable test results for patients. Analytical validation involves testing sensitivity, precision, linear dynamic range, and reproducibility of the finalized assay... |
| |
» More |
|
|
|
Spotlight on Oncotype DX Colon Cancer Assay Genes: Cell Cycle and Ki67 |
| |
In contrast to the Oncotype DX Breast Cancer Assay, where higher expression of cell cycle genes (STK15, MYBL2, Ki-67 and CCNB1) is associated with increased risk of recurrence [1-2], higher expression of the colon cell cycle genes (cMYC and Ki-67 and MYBL2)... |
| |
» More |
|
|
|
|
Intro to Patient Ambassador |
| |
A sergeant in the police force and father of four, Dan always considered himself to be in good health. But in 2010 when he attempted to train for a local bike race, one that he had easily completed the year before, he found his energy levels weren't the same... |
| |
» More |
|
|
|
What’s to Come/Future Products |
| |
With the 12-gene Oncotype DX Colon Cancer Assay as the foundation of our Colon Cancer program, Genomic Health is committed to conducting further research to build on our understanding of the underlying biology in colon cancer... |
| |
» More |
|
|
|
In the Community: An Interview with Dr. Sullivan |
| |
Dr. James Sullivan, a colorectal surgeon at St. Francis Hospital in Great Neck, New York, recently sat down with Genomic Health to talk about his experiences with the Oncotype DX Colon Cancer Assay. |
| |
» More |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Archived Articles |
|
|
|
How are stage II colon cancer patients being assessed for their recurrence risk today? |
| |
» More |
|
|
|
The Oncotype DX Colon Cancer Assay |
| |
» More |
|
|
|
Poster Presentations at ASCO-GI 2011 |
| |
» More |
|
|
|
Poster Presentation at ESMO 2010 |
| |
» More |
|
|
|
Fibroblast Activation Protein |
| |
» More |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
 |
Patient Case Study |
|
|
|
|
| Patient Case |
|
| 78-year-old female with 4.8-cm tumor |
|
| Tumor Type: Adenocarcinoma of the Colon |
|
| Tumor Size: 4.8 cm |
|
| T Stage: 3 |
|
| Histologic Grade: 3 |
|
| Lymph Node Status: Negative |
|
| Number of Lymph Nodes Assessed: 3 |
|
| Mismatch Repair (MMR) Status: MMR-P(IHC) |
|
| Lymphovascular Invasion: No |
|
| Perforation: No |
|
| Obstruction: N/A |
|
|
|
|
| |
» More |
|
|
|
|
|
|
|
|
|
|
|
|
|
Copyright 2011 Genomic Health, Inc. All Rights Reserved.
301 Penobscot Drive, Redwood City, CA 94063, Tel: (650) 556-9300, Fax: (650) 556-1132
|
|
|
|
|
|
|
|
|
